Scientific publications

  • Scientific publications

Our reviews on pulmonary drug delivery

La chimiothérapie inhalée – Partie 1 : Concept et challenges technologiques actuels
R. Rosière, J. Hureaux, V. Levet, K. Amighi, N. Wauthoz. Revue des Maladies Respiratoires 35(4), 357-377 (2018).

La chimiothérapie inhalée – Partie 2 : Clinique et applications potentielles
R. Rosière, J. Hureaux, V. Levet, K. Amighi, N. Wauthoz. Revue des Maladies Respiratoires 35(4), 357-377 (2018).

Recent developments in inhaled Triazoles against invasive pulmonary aspergillosis
R. Merlos, K. Amighi and N. Wauthoz. Curr Fungal Infect Rep 8(4), 331-342 (2014).

Phospholipids in pulmonary drug delivery
N. Wauthoz and K. Amighi,. Eur. J. Lipid Sci. Technol., 116, 1114–1128 (2014).

Formulation Strategies for Pulmonary Delivery of Poorly Soluble Drugs
N. Wauthoz and K. Amighi,. IN: Pulmonary Drug Delivery, Advances and Challenges, Edit. Wiley 2015, Chapter 5, pp 87-121.

Formulations for intranasal delivery of pharmacological agents to combat brain disease: a new opportunity to tackle GBM?
M. Van Woensel, N. Wauthoz, R. Rosière, K. Amighi, V. Mathieu, F. Lefranc, S. Van Gool, S. De Vleeschouwer, Cancers, 5(3), 1020-1048 (2013).

Inhaled proteins: challenges and perspectives
F. Depreter, G. Pilcer, K. Amighi. Int. J. Pharm., 447(1-2), 251-80 (2013).

Lactose characteristics and the generation of the aerosol
G. Pilcer, N. Wauthoz, K. Amighi,. Adv. Drug. Del. Rev., 64, 233–256 (2012).

Formulation strategy and use of excipients in pulmonary drug delivery
G. Pilcer, K. Amighi. Int. J. Pharm., 392, 1-19 (2010).

Our scientific publications on cisplatin-based DPI

Platinum pharmacokinetics in mice following inhalation of cisplatin dry powders with different release and lung retention properties
V. Levet, R. Merlos, R. Rosière, K. Amighi, N. Wauthoz. Int. J. Pharm., 517, 359-372 (2017).

 Development of controlled-release cisplatin dry powders for inhalation against lung cancers
V. Levet, R. Rosière, R. Merlos, L. Fusaro, G. Berger, K. Amighi, N. Wauthoz. Int. J. Pharm., 515, 209-220 (2016).

Our scientific publications on lung cancer cell targeting – Paclitaxel-based DPI

New folate-grafted chitosan derivative to improve delivery of paclitaxel-loaded solid lipid nanoparticles for lung tumor therapy by inhalation
R. Rosière, M. Van Woensel, M. Gelbcke, V. Mathieu, J. Hecq, T. Mathivet, M. Vermeersch, P. Van Antwerpen, K. Amighi, N. Wauthoz. Mol Pharm, 15(3), 899-910 (2018)

Development and evaluation of well-tolerated and tumor penetrating micelle-based dry powders for inhaled anti-cancer chemotherapy
R. Rosière, M. Van Woensel, V. Mathieu, I. Langer, T. Mathivet, M. Vermeersch, K. Amighi and N. Wauthoz. Int. J. Pharm. 501(1-2), 148-159 (2016).

New dry powders for inhalation containing temozolomide-based nanomicelles for improved lung cancer therapy
R. Rosière, M. Gelbcke, V. Mathieu, P. Van Antwerpen, K. Amighi, N. Wauthoz. Int. J. Oncol., 47(3), 1131-42 (2015).

Our scientific publications on DPI delivery in asthma and COPD

Proposed algorithm for healthcare professionals based on product characteristics and in vitro performances in different use conditions using formoterol-based marketed products for inhalation
N. Wauthoz, I. Hennia, B. Dejaeger, S. Ecenarro, K. Amighi. Int. J. Pharm. 530, 415-429 (2017).

Evaluation of the content homogeneity and dispersion properties of fluticasone DPI compositions
T. Sebti, F. Vanderbist and K. Amighi. J. Drug Del. Sc. Technol., 17(3) 223-229 (2007).

Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation
T. Sebti, G. Pilcer, B. Van Gansbeke, S. Goldman, A. Michils, F. Vanderbist and K. Amighi. Eur. J. Pharm. Biopharm., 64, 26-32 (2006).

Our scientific publications on DPI delivery of antibiotics

Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis
G. Pilcer, V. De Bueger K. Traina, H. Traore, T. Sebti, F. Vanderbist, K. Amighi. Int. J. Pharm., 451(1-2), 112-20 (2013).

New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients
G. Pilcer, R. Rosière, K. Traina, T. Sebti, F. Vanderbist, K. Amighi. J. Pharm. Science, 102(6), 1836-46 (2013).

Spray-dried carrier-free dry powder tobramycin formulations with improved dispersion properties
G. Pilcer, F. Vanderbist, K. Amighi. J. Pharm. Sci., 98, 1463-1475 (2009).

Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery
G. Pilcer, F. Vanderbist, K. Amighi. Int. J. Pharm., 365, 162-169 (2009).

Correlations between cascade impactor analysis and laser diffraction techniques for the determination of the particle size of aerosolised powder formulations
G. Pilcer, F. Vanderbist, K. Amighi. Int. J. Pharm., 358, 75-81 (2008).

Pharmacoscintigraphic and pharmacokinetic evaluation of Tobramycin DPI Formulations in Cystic Fibrosis Patients
G. Pilcer, J. Goole, B. Van Gansbeke, D. Blocklet, Ch. Knoop, F. Vanderbist, K. Amighi. Eur. J. Pharm. Biopharm. 68, 413-421 (2008).

Formulation and characterisation of lipid-coated tobramycin particles for dry powder inhalation
G. Pilcer, T. Sebti and K. Amighi. Pharm. Res. 23(5) 931-940 (2006).

Our scientific publications on DPI delivery of antifungal drugs

Optimization and Scaling-Up of ITZ-based Dry Powders for Inhalation
R. Merlos, N. Wauthoz, V. Levet, L. Belhassan, T. Sebti, F. Vanderbist, K. Amighi. J. Drug Deliv. Sci. Technol., 37, 147-157 (2017).

Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention
C. Duret, N. Wauthoz, R. Merlos, T. Sebti, F. Vanderbist and K. Amighi. Eur. J. Pharm. Biopharm., 86(1): 46-54 (2014).

New Inhalation-Optimized Itraconazole Nanoparticle-Based Dry Powders for the Treatment of Invasive Pulmonary Aspergillosis,
C. Duret, N. Wauthoz, T. Sebti, F. Vanderbist and K. Amighi. Int. J. Nanomedicine 7, 5475–5489 (2012).

New Respirable and Fast Dissolving Itraconazole Dry Powder Composition for the Treatment of Invasive Pulmonary Aspergillosis
C. Duret, N. Wauthoz, T. Sebti, F. Vanderbist and K. Amighi. Pharm. Research, 29, 2845–2859 (2012).

Itraconazole-mannitol solid dispersions for inhalation with enhanced dissolution and dispersion properties
C. Duret, N. Wauthoz, T. Sebti, F. Vanderbist and K. Amighi. Int. J. Pharm., 428(1–2), 103-113 (2012).

In vitro and in vivo evaluation of a dry powders endotracheal insufflator device for use in dose dependent preclinical studies in mice
C. Duret, R. Merlos, N. Wauthoz, J. Goole, C. Maris, I. Rolland, T. Sebti, F. Vanderbist and K. Amighi. Eur. J. Pharm. Biopharm., 81(3), 627-634 (2012).

Our scientific publications on DPI delivery of peptides, proteins and monoclonal antibodies

Comparative pharmacoscintigraphic and pharmacokinetic evaluation of two new formulations of inhaled insulin in type 1 diabetic patients
F. Depreter, A. Burniat, D. Blocklet, S. Lacroix, M. Cnop, F. Fery, N. Van Aelst, G. Pilcer, M. Deleers, S. Goldman, and K. Amighi. Eur. J. Pharm. Biopharm. 80(1) 4-13 (2012).

Formulation and in vivo evaluation of highly dispersible insulin dry powder formulations for lung administration
F. Depreter, K. Amighi. Eur. J. Pharm. Biopharm., 76 (3), 454-463, (2010).

Our scientific publications on Nose-to-brain delivery

Development of coated liposomes loaded with ghrelin for nose-to-brain delivery for the treatment of cachexia
L. Salade, N. Wauthoz, C. De Vriese, K. Amighi, J. Goole. Int J Nanomed 12, 8531-8543 (2017).

Chitosan-coated liposome dry-powder formulations loaded with ghrelin for nose-to-brain delivery
L. Salade, N. Wauthoz, M. Vermeersch, K. Amighi, J. Goole. Eur. J. Pharm. Biopharm., 129, 257-266 (2018).

Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration
M. Van Woensel, N. Wauthoz, R. Rosière, V. Mathieu, R. Kiss, F. Lefranc, B. Steelant, S. W. Van Gool, T. Mathivet, H. Gerhardt, K. Amighi and S. De Vleeschouwer. J. Control. Rel., 227 (10) 71-81 (2016).

Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy
M. Van Woensel, T. Mathivet, N. Wauthoz, R. Rosière, A.D. Garg Abhishek, P. Agostinis, V. Mathieu, R. Kiss, F. Lefranc, L. Boon, J. Belmans, S.W. Van Gool, H. Gerhardt, K. Amighi, S. De Vleeschouwer. Scientific Reports 7(1), 1217 (2017).

Our scientific publications on New fillers and/or carriers for DPI

Preparation and in vitro evaluation of new lipidic carriers and fillers for inhalation
T. Sebti and K. Amighi. Eur. J. Pharm. Biopharm. 63(1), 51-58 (2006).

Our scientific publications on DPI delivery of other anticancer drugs

Temozolomide-based dry powder formulations for lung tumor-related inhalation treatment
N. Wauthoz, P. Deleuze, A. Saumet, C. Duret, R. Kiss, K. Amighi. Pharm. Res., 28(4) 762-775 (2011).

In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy
N. Wauthoz, P. Deleuze, J. Hecq, I. Roland, I. Adanja, O. Debeir, C. Decaestecker, V. Mathieu, R. Kiss, K. Amighi. Eur. J. Pharm. Science 39, 402-411 (2010).

Scientific international meetings and congresses

  1. Formulation strategies of dry powders related to the lung diseases
    Wauthoz N., Amighi K. SimInhale COST action MP1404 Summer School 2018 and 5th Workshop on Pulmonary Drug Delivery. Dublin (Ireland) –September 3-6th, 2018 (Oral).
  2. Impact of capsule type on the aerodynamic performances of a fluticasone-based dry powder under optimal and suboptimal inhalation airflows
    N. Wauthoz, I. Hennia, S. Ecenarro, K. Amighi. Drug Delivery to the Lung 2017, Edinburg (UK) – 6-8 December 2017 (Poster)
  3. Development of paclitaxel nanocrystal-based dry powder formulations for targeted therapy of lung tumours by inhalation
    R. Rosière, S. Chraibi, S. Albasry, M. Vermeersch, K. Amighi and N. Wauthoz. Drug Delivery to the Lungs 2017, Edinburgh, UK, December 2017 (Poster)
  4. Innovative dry powder formulations for inhalation to improve therapeutic outcomes of lung tumours
    R. Rosière. 2nd Annual Inhalation & Respiratory Drug Delivery Congress, London, UK, May 2017 (Oral)
  5. Impact of Capsule Type on the Aerodynamic Performance of Dry Powder Formulations for Inhalation
    N. Wauthoz, K. Amighi. Workshop at RDD Europe 2017 Antibes (France) – 26th April 2017 (Poster).
  6. Development of a dry-powder formulation with ghrelin-loaded liposomes for nose-to-brain delivery
    L. Salade, N. Wauthoz, C. De Vriese, K. Amighi, J. Goole. 2nd European Conference on Pharmaceutics: Drug Delivery, Krakow (Poland) – 3-4 April 2017 (Poster)
  7. A Comparative Evaluation of the Aerosolization Performances of Marketed Fluticasone Multi-Unit and Single-Unit Dry Powder Inhalers (DPIs): The Effects of Product Use Life, Suboptimal Airflow and a Hot/Humid Environment
    N. Wauthoz, I. Hennia, S. Ecenarro, K. Amighi. Respiratory Drug Delivery Europe 2017 (Poster)
  8. Tolerance of Cisplatin Dry Powders for Inhalation and Efficacy on an Orthotopic Grafted Lung Tumor Preclinical Model
    V. Levet, R. Rosière, J. Hecq, I. Langer, K. Amighi, N. Wauthoz. Respiratory Drug Delivery Europe 2017, Antibes, France, May 2017 (poster)
  9. Impact of different capsules for dry powder inhalers on the aerodynamic performances of formoterol-based binary and ternary blends
    N. Wauthoz, I. Hennia, S. Ecenarro, K. Amighi. Drug Delivery to the Lung 2016, Edinburg (UK), 7-9 December 2016 (Poster)
  10. Local and systemic pharmacokinetic evaluation of immediate-release and controlled-release cisplatin dry powders for inhalation against lung cancer
    V. Levet, R. Rosière, K. Amighi & N. Wauthoz. Drug Delivery to the Lung 2016, Edinburg (UK), 7-9 December 2016 (Poster)
  11. New lung tumor-penetrating nanocarrier designed for aerosolized chemotherapy
    R. Rosière, M. Van Woensel, V. Mathieu, T. Mathivet, K. Amighi and N. Wauthoz. Drug Delivery to The Lungs Conference 2016, Edinburgh (UK), December 2016 (Oral)
  12. Influence of Flow Rate and Usage in Drastic Condition on the Aerodynamic Performance of a Formoterol Dry Powder Formulation using different kinds of Capsules for Inhalation
    N. Wauthoz, I. Hennia, S. Ecenarro, K. Amighi. AAPS2016 Denver (USA), 13-17 November 2016, (Poster)
  13. Development of Cisplatin-based Dry Powder for Inhalation with controlled Release Properties for the Lung Cancer Therapy
    V. Levet, K. Amighi, N. Wauthoz. Respiratory Drug Delivery 2016, Phoenix Arizona (USA), 17-21 April 2016 (Poster)
  14. Influence of Different Capsules for Inhalation on the Aerodynamic Performance of Formoterol Dry Powder Formulation at Different Flow Rates
    N. Wauthoz, I. Hennia, F. Diez, K. Amighi. Respiratory Drug Delivery 2016, Phoenix Arizona (USA), 17-21 April 2016 (Poster)
  15. Development of siRNA-loaded Chitosan Nanoparticles targeting Galectin-1 for the treatment of Glioblastoma Multiforme via Intranasal Administration
    M. Van Woensel, N. Wauthoz, R. Rosiere, V. Mathieu, R. Kiss, F. Lefranc, B. Steelant, S.W. Van Gool, T. Mathivet, H. Gerhardt, K. Amighi, S. De Vleeschouwer. Respiratory Drug Delivery 2016, Phoenix Arizona (USA), 17-21 April 2016 (Poster on the podium + VCU RDD Peter R. Byron Graduate Student Award)
  16. Development and evaluation of ghrelin-loaded liposomes for nose to brain delivery
    L. Salade, N. Wauthoz, C. De Vriese, K. Amighi, J. Goole. 10th World Meeting on Pharmaceutics, Biopharmaceutis and Pharmaceutical Technology, Glasgow (UK), April 4-7th, 2016 (Poster)
  17. Evaluation of the aerodynamic performance of formoterol dry powder using different capsules for inhalation: hypromellose versus gelatin from Qualicaps® and Capsugel®
    N. Wauthoz, I. Hennia, M. Deleers, F. Diez & K. Amighi. Drug Delivery to the Lung 2015, Edinburgh (UK), 9-11 December 2015 (Poster)
  18. A Comparative Evaluation of Formoterol-based Marketed Inhaled Medicines throughout the Device Life, focusing on Inspiratory Airflow and High Temperature and Humidity use Conditions
    N. Wauthoz, I. Hennia, M. Deleers, F. Diez, K. Amighi. AAPS2015 Orlando (USA), 25-29 October 2015 (Poster)
  19. Inhaler Device Selection: comparison of capsule-based DPIs, pMDIs and Multi-dose DPIs
    Wauthoz N., Hennia I., Deleers M., Diez F., Amighi K. Workshop at AAPS2015 Orlando (USA), 26th October 2015.
  20. Innovative dry itraconazole-based solid dispersion for inhalation to combat pulmonary aspergillosis: from the laboratory bench to the industrial scale
    N. Wauthoz, C. Duret, R. Merlos, T. Sebti, F. Vanderbist, K. Amighi, Inhaled Therapies for Tuberculosis and other infectious diseases – 3rd World Meeting- Parma (Italy), 14-16 October 2015 (Poster)
  21. Aerodynamic properties and pharmacokinetics of capreomycin oleate supergenerics,
    A. Schoubben, N. Wauthoz, F. Ianni, P. Blasi, K. Amighi, M. Ricci. Inhaled Therapies for Tuberculosis and other infectious diseases – 3rd World Meeting- Parma (Italy) -14-16 October 2015. (oral)
  22. The Behavior of Capsule-Based DPIs Among Marketed Inhaled Medicines – A Comparative Case Using Formoterol
    Wauthoz N. Capsule-based Inhalers: Understanding the Science – Workshop London (England) 9th June 2015. (Oral)
  23. Inhaler Device Selection : comparison of capsule-based DPIs, pMDIs and Multi-dose DPIs
    Wauthoz N., Hennia I., Deleers M., Diez F., Amighi K. Workshop at RDD Europe 2015 Antibes (France) -05 May 2015 (oral).
  24. New Dry Powders for Inhalation containing Chitosan Derivative-Coated Solid Lipid Nanoparticles for Targeted Delivery to Lung Cancer Cells
    R. Rosière, K. Amighi and N. Wauthoz. Respiratory Drug Delivery Symposium, Nice (France) May 5-8, 2015 (Poster).
  25. Scaling-up of an Itraconazole-based Dry Powder for Inhalation from a Lab-sized Büchi Mini Spray Dryer B-290 to a Pilot Mobile Minor Spray Dryer
    R. Merlos, N. Wauthoz, L. Belhassan, T. Sebti, K. Traina, F. Vanderbist, K. Amighi. Respiratory Drug Delivery Symposium, Nice (France) May 5-8, 2015 (Poster).
  26. Nanomicelle-based dry powders for inhalation for targeted delivery to lung cancer cells: in vitro evaluation and in vivo local pulmonary tolerance on healthy mice
    R. Rosière, M. van Woensel, I. Langer, V. Mathieu, K. Amighi, N. Wauthoz. European Conference on Pharmaceutics: Drug Delivery, 13-14 April, 2015, Reims, France (Poster).
  27. Intranasal delivery of anti-Galectin-1 formulation to increase the efficiency of chemo- and immunotherapy for glioblastoma
    M. Van Woensel, N. Wauthoz, R. Rosière, K. Amighi, V. Mathieu, F. Lefranc, S. Van Gool, T. Mathivet, and S. de Vleeschouwer, European Conference on Pharmaceutics: Drug Delivery, 13-14 April, 2015, Reims, France (Poster).
  28. Dry Powders for inhalation: Which Device, Capsule, Formulation?
    N. Wauthoz. Capsule-based Inhalers: Understanding the Science – Workshop Basel (Suisse) November 25th, 2014
    Development of Folate Receptor-Targeted Nanoparticles Containing Temozolomide for Lung Cancers Therapy by Dry Powder Inhalation
    R. Rosière, N. Wauthoz, P. Van Antwerpen, M. Gelbcke, K. Amighi. Respiratory Drug Delivery Symposium, Puerto Rico, 5-8 May 2014 (poster).
  29. Advances in pulmonary drug delivery
    K. Amighi, N. Wauthoz. 9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology”, Lisbon, Portugal 31 March – 4 April, 2014 (Oral).
  30. Development of nanoparticle formulations composed by new folate receptor-targeted excipients and temozolomide for the lung cancers therapy by inhalation
    R. Rosière, N. Wauthoz, P. Van Antwerpen, M. Gelbcke, K. Amighi. 9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lisbon (Portugal), 31 March – 4 April, 2014 (poster).
  31. La délivrance pulmonaire : une nouvelle voie d’accès pour les médicaments ? Etat de l’art, réalisations et perspectives
    K. Amighi. Conférences de l’Académie Royale de Médecine de Belgique, 29 mars 2014 (Orale).
  32. A New Inhaled Itraconazole Solid Dispersion for Inhalation Against Invasive Pulmonary Aspergillosis
    C. Duret, N. Wauthoz, R. Rosière, R. Merlos, T. Sebti, F. Vanderbist, K. Amighi, 3rd Conference on “Innovation in Drug Delivery: Advances in Local Drug Delivery”, Pisa (Italy), 22-25 September, 2013 (Oral).
  33. Phospholipids as pulmonary excipient
    N. Wauthoz and K. Amighi, 3rd Symposium on Phospholipids in Pharmaceutical Research, Heidelberg, Germany, 17 September 2013 (oral).
  34. Prophylactic efficacy of inhaled Itraconazole-mannitol dried solid dispersion against invasive pulmonary aspergillosis
    C. Duret, N. Wauthoz, R. Rosière, T. Sebti, F. Vanderbist, K. Amighi, Respiratory Drug Delivery Symposium, Berlin, Germany, 21-24 May 2013 (poster).
  35. Temozolomide by inhalation for the treatment of lung tumors: Preclinical investigation and development of dry powder formulations for inhalation
    N. Wauthoz, R. Kiss, K. Amighi. Nanomedicine in Oncology Workshop, 26th to 29th September 2012, Berder, France (oral).
  36. Itraconazole Nanoparticle-Based Dry Powders for Inhalation
    C. Duret, N. Wauthoz, T. Sebti, F. Vanderbist, K. Amighi. Respiratory Drug Delivery Symposium, Arizona, USA, 14-17 May 2012 (poster).
  37. Clinical Evaluation of Two New Formulations of Inhaled Insulin in Type 1 Diabetic Patients
    F. Depreter, A. Burniat, D. Blocklet, S. Lacroix, M. Cnop, F. Fery, N. Van Aelst, G. Pilcer, M. Deleers, S. Goldman, K. Amighi. 8th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology”, Istanbul, Turkey 19-22 March, 2012 (poster).
  38. In vitro and in vivo evaluation of a dry powder endotracheal insufflator device for use in dose dependent preclinical studies in mice
    C. Duret, N. Wauthoz, J. Goole, T. Sebti, F. Vanderbist, K. Amighi, 8th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology”, Istanbul, Turkey 19-22 March, 2012 (poster).
  39. Development and Local Delivery of Temozolomide Dry Powders for Inhalation against Lung Tumors
    N. Wauthoz, P. Deleuze, J. Hecq, A. Saumet, C. Duret, I. Roland, S. Saussez, I. Adanja, O. Debeir, C. Decaestecker, V. Mathieu, R. Kiss, K. Amighi. 8th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Istanbul, Turkey 19-22 March, 2012 (Oral presentation).
  40. New dry powder combination for inhalation of two antibiotics with high deposition properties
    G. Pilcer, F. Vanderbist, T. Sebti, B. Cahay, B. Streel, K. Amighi. 8th World Meeting on Pharmaceutics Biopharmaceutics and Pharmaceutical Technology, Istanbul, Turkey, March 19-22, 2012 (poster).
  41. The use of phospholipids as excipient in the development of formulation for inhalation therapy. C. Duret, N. Wauthoz, G. Pilcer, F. Depreter, T. Sebti, K. Amighi. Symposium on Phospholipids in Pharmaceutical Research, Heidelberg, Germany, September 12-13, 2011 (poster).
  42. Temozolomide-based dry powder formulations for lung tumor-related inhalation treatments
    N. Wauthoz, P. Deleuze, A. Saumet, C. Duret, R. Kiss, K. Amighi. Poster session presented at The Pharmaceutical Science Fair & Exposition 3rd edition: 13-17 June 2011, Prague (poster).
  43. Inflammation induced by LPS inhalation depends on the particle size
    V. Doyen, G. Pilcer, P.H.D. Dinh, S. D’Hondt, F. Corazza, A. Bernard, K. Amighi and O. Michel. 30th Congress of the European Academy of Allergy and Clinical Immunology, Istanbul, Turkey, 11-15 June 2011 (poster).
  44. Lactose characteristics and the generation of the aerosol
    K. Amighi. International meeting on Lactose as a carrier for Inhalation Products, 26-28 September 2010, Parma, Italy (oral).
  45. In vivo assessment of temozolomide delivery systems for inhalation therapy of lung cancer
    N. Wauthoz, K. Amighi. 7th World Meeting on Pharmaceutics Biopharmaceutics and Pharmaceutical Technology, La Valletta, Malta, 8-11 March 2010 (oral).
  46. Development of spray-dried insulin particles for inhalation using lipid excipients
    F. Depreter and K. Amighi. 7th World Meeting on Pharmaceutics Biopharmaceutics and Pharmaceutical Technology, La Valletta, Malta, 8-11 March 2010 (poster).
  47. Highly dispersive tobramycin dry powder formulations for inhalation
    G. Pilcer and K. Amighi. 7th World Meeting on Pharmaceutics Biopharmaceutics and Pharmaceutical Technology, La Valletta, Malta, 8-11 March 2010 (poster).
  48. Formulation and characterization of lipid-coated insulin dry particles for lung administration
    F. Depreter, K. Amighi. 14th Forum of Pharmaceutical Sciences, Blankenberge, Belgium, May 2009.
  49. New highly dispersive carrier-free dry powder formulations for inhalation
    G. Pilcer, F. Vanderbist and K. Amighi. 36th Meeting and Annual Exposition of the Controlled Release Society, Copenhagen, Denmark, 18-22 July 2009 (poster).
  50. Development and evaluation of the use of nanoparticles for dry powder inhalation
    G. Pilcer, F. Vanderbist and K. Amighi. 6th World Meeting on Pharmaceutics Biopharmaceutics and Pharmaceutical Technology, Barcelona, Spain 7-10 April 2008 (poster).
  51. La Tobramycine inhalée : nébulisation versus poudre sèche.
    G. Pilcer and K. Amighi. La mucoviscidose au quotidien (10ème édition), Centre de référence de la mucoviscidose, 24 novembre 2007 (Oral).
  52. Development and in vivo evaluation of dry powder tobramycin formulations in the cystic fibrosis treatment
    G. Pilcer and K. Amighi.13th Forum of Pharmaceutical Sciences, Spa, Belgium, 11-12 October 2007 (Oral).
  53. Lung deposition and pharmacokinetic of tobramycin dry powder formulations in cystic fibrosis
    G. Pilcer, F. Vanderbist and K. Amighi. 34th Annual Meeting & Exposition of the controlled release society, July 7-11, 2007, Long Beach, California U.S.A (poster).
  54. Highly dispersive tobramycin DPI formulations obtained by coating Micronized particles by physiological lipids
    G. Pilcer, T. Sebti and K. Amighi. 5th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, March 27-30th, 2006, Geneva, Switzerland (Oral).
  55. Gamma scintigraphic and pharmacokinetic study for assessing pulmonary deposition of budesonide from solid lipid formulations
    T. Sebti., G. Pilcer, B. Van Gansbeke, S. Goldman, A. Michils and K. Amighi. 5th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, March 27-30th, 2006, Geneva, Switzerland (poster).
  56. Solid Lipid Particles as pharmaceutically acceptable fillers or carriers for inhalation
    Sebti Th., Amighi K. PharmSciFair – The Pharmaceutical Science Fair & Exposition, June 12-17, 2005, Nice, France (Oral).
at in leo. ut Aenean leo felis ut Sed venenatis